MiNK Therapeutics, Inc. Contracts & Agreements
29 Contracts & Agreements
- Business Finance (9 contracts)
- Business Operations (3)
- Human Resources (13)
- Intellectual Property (1)
- Uncategorized (3)
- Form of Convertible Promissory Note by and between the Registrant and Agenus Inc., dated February 12, 2024 (Filed With SEC on March 21, 2024)
- Convertible Promissory Note Purchase Agreement by and between the Registrant and Agenus Inc., dated February 12, 2024 (Filed With SEC on March 21, 2024)
- Amended and Restated Intercompany Services Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated August 2, 2022, with effect April 1, 2022 (Filed With SEC on August 15, 2022)
- MiNK Therapeutics, Inc. Executive Change of Control Plan (Filed With SEC on June 14, 2022)
- Description of Securities (Filed With SEC on March 18, 2022)
- Executive Employment Agreement between the Registrant and Jennifer Buell, dated March 3, 2022 (Filed With SEC on March 18, 2022)
- Executive Employment Agreement between the Registrant and Marc van Dijk, dated March 2, 2022 (Filed With SEC on March 18, 2022)
- Form of Underwriting Agreement (Filed With SEC on October 12, 2021)
- Specimen stock certificate evidencing shares of common stock (Filed With SEC on October 12, 2021)
- Amendment to Convertible Promissory Note, by and between MINK Therapeutics, Inc. and Agenus Inc., dated September 29, 2021 (Filed With SEC on October 12, 2021)
- MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on October 12, 2021)
- MiNK Therapeutics, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on October 12, 2021)
- MiNK Therapeutics, Inc. 2021 Cash Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Restricted Stock Unit Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Non-Statutory Stock Option Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Incentive Stock Option Agreement under the MiNK Therapeutics, Inc. 2021 Equity Incentive Plan (Filed With SEC on October 12, 2021)
- Form of Indemnification Agreement, to be entered into by and between the Company and each of its directors and officers (Filed With SEC on October 12, 2021)
- Intellectual Property Assignment and License Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated September 10, 2021 (Filed With SEC on September 14, 2021)
- Intercompany General & Administrative Services Agreement, by and between Agenus Inc. and MiNK Therapeutics, Inc., dated September 10, 2021 (Filed With SEC on September 14, 2021)
- Convertible Promissory Note, by and between AgenTus Therapeutics, Inc. and Agenus Inc., dated February 11, 2021 (Filed With SEC on September 14, 2021)
- Convertible Promissory Note Purchase Agreement, by and between AgenTus Therapeutics, Inc. and Agenus Inc., dated February 11, 2021 (Filed With SEC on September 14, 2021)
- AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on September 14, 2021)
- Form of Restricted Stock Award Agreement under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on September 14, 2021)
- Form of Non-Qualified Stock Option Award Agreement for Employees under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on September 14, 2021)
- Form of Non-Qualified Stock Option Award Agreement for Non-Employees under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on September 14, 2021)
- Form of Incentive Stock Option Award Agreement under the AgenTus Therapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on September 14, 2021)
- Letter Agreement between AgenTus Therapeutics, Inc. and Walter Flamenbaum, M.D., dated November 14, 2019 (Filed With SEC on September 14, 2021)
- Letter Agreement between AgenTus Therapeutics, Inc. and Patrick Jordan, dated November 12, 2020 (Filed With SEC on September 14, 2021)
- Restricted Stock Award Agreement between AgenTus Therapeutics, Inc. and Patrick Jordan, dated November 5, 2020 (Filed With SEC on September 14, 2021)
